TEVA Relative Valuation
TEVA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TEVA is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for TEVA's competitors is 1.14, providing a benchmark for relative valuation. Teva Pharmaceutical Industries Ltd Corp (TEVA) exhibits a P/S ratio of 1.14, which is 0.00% above the industry average. Given its robust revenue growth of 1.89%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Teva Pharmaceutical Industries Ltd (TEVA) currently overvalued or undervalued?
What is Teva Pharmaceutical Industries Ltd (TEVA) fair value?
How does TEVA's valuation metrics compare to the industry average?
What is the current P/B ratio for Teva Pharmaceutical Industries Ltd (TEVA) as of May 19 2025?
What is the current FCF Yield for Teva Pharmaceutical Industries Ltd (TEVA) as of May 19 2025?
What is the current Forward P/E ratio for Teva Pharmaceutical Industries Ltd (TEVA) as of May 19 2025?